Campbell & Co Investment Adviser’s Xenon Pharmaceuticals XENE Stock Holding History

Campbell & Co Investment Adviser’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.06M	Buy	18,156 +2,051	+13%	+$94.5K	0.06%	492
2025 Q4	$722K	Sell	16,105 -12,564	-44%	-$528K	0.03%	694
2025 Q3	$1.15M	Buy	+28,669	New	+$1.01M	0.09%	363
2024 Q4	–	Sell	-7,339	Closed	-$289K	–	1417
2024 Q3	$289K	Sell	7,339 -16,721	-69%	-$674K	0.02%	916
2024 Q2	$938K	Buy	+24,060	New	+$962K	0.08%	391
2024 Q1	–	Sell	-17,973	Closed	-$828K	–	1409
2023 Q4	$828K	Buy	+17,973	New	+$635K	0.07%	471

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Campbell & Co Investment Adviser's XENE Position: Q1 2026 in Review

Campbell & Co Investment Adviser increased its Xenon Pharmaceuticals (XENE) stake by 13% in Q1 2026, buying an estimated $94.5K and bringing the position to 18,156 shares worth $1.06M. The position accounts for 0.06% of the portfolio, ranked #492.

Campbell & Co Investment Adviser first reported a position in XENE in Q4 2023 and has held it in 6 quarters since. The position peaked at $1.15M in Q3 2025. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

Campbell & Co Investment Adviser held 18,156 shares of Xenon Pharmaceuticals worth $1.06M as of Q1 2026.
Campbell & Co Investment Adviser bought 2,051 Xenon Pharmaceuticals shares in Q1 2026, an estimated $94.5K.
Xenon Pharmaceuticals made up 0.06% of Campbell & Co Investment Adviser's portfolio in Q1 2026, its #492 holding.
Campbell & Co Investment Adviser first reported a position in Xenon Pharmaceuticals in Q4 2023 and has held it in 6 quarters since.
Campbell & Co Investment Adviser's Xenon Pharmaceuticals position peaked at $1.15M in Q3 2025.
290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2026, filed 15 May 2026.